Dynavax Technologies Corporation (NASDAQ:DVAX)‘s stock had its “outperform” rating reissued by analysts at William Blair in a report issued on Wednesday. They presently have a $30.00 price objective on the biopharmaceutical company’s stock. William Blair’s target price suggests a potential upside of 74.42% from the stock’s previous close.

Several other analysts have also commented on DVAX. Royal Bank Of Canada raised their target price on Dynavax Technologies Corporation from $6.00 to $7.00 and gave the stock a “sector perform” rating in a report on Tuesday, May 9th. ValuEngine lowered Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research raised Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Monday, July 10th. Cowen and Company reissued an “outperform” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday, July 27th. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $27.00 in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Dynavax Technologies Corporation currently has an average rating of “Hold” and an average target price of $25.84.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded down 7.77% on Wednesday, hitting $17.20. The company had a trading volume of 3,851,432 shares. The company’s market capitalization is $854.84 million. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $18.25. The stock’s 50-day moving average is $10.50 and its 200 day moving average is $6.66.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. Dynavax Technologies Corporation had a negative return on equity of 101.98% and a negative net margin of 1,323.99%. During the same period last year, the company earned ($0.75) earnings per share. Equities analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/09/william-blair-reiterates-outperform-rating-for-dynavax-technologies-corporation-nasdaqdvax.html.

Several hedge funds have recently modified their holdings of DVAX. JPMorgan Chase & Co. raised its stake in shares of Dynavax Technologies Corporation by 344.8% in the second quarter. JPMorgan Chase & Co. now owns 505,227 shares of the biopharmaceutical company’s stock worth $4,876,000 after buying an additional 391,632 shares in the last quarter. Hikari Power Ltd raised its stake in shares of Dynavax Technologies Corporation by 67.5% in the second quarter. Hikari Power Ltd now owns 83,755 shares of the biopharmaceutical company’s stock worth $808,000 after buying an additional 33,755 shares in the last quarter. Swiss National Bank raised its stake in shares of Dynavax Technologies Corporation by 25.5% in the second quarter. Swiss National Bank now owns 70,978 shares of the biopharmaceutical company’s stock worth $685,000 after buying an additional 14,400 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Dynavax Technologies Corporation by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Dynavax Technologies Corporation by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares in the last quarter. 56.05% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.